FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating hormone (rhFSH) under development by Ferring Pharmaceuticals. It is intended for controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. In previous trials the exposure to and dose proportionality of FE 999049 in a clinically relevant dose range in Caucasian and Japanese healthy women have been shown to be very similar. This is a trial in healthy Chinese women investigating the pharmacokinetics, safety, and tolerability of a single subcutaneous dose of FE 999049.

Inclusion Criteria:

• Female of Chinese origin, with two ethnic Chinese parents and four ethnic Chinese grandparents 21-40 years of age (both inclusive)
• Willing to stop using combined oral contraceptives (COC) in relation to the first DECAPEPTYL Depot administration on Day -28
• Agrees to use a double barrier method of contraception between Day -63 and Day 28, if not abstinent. A double barrier method of contraception should also be used after Day 28 until menses resumes or until another contraceptive method has been established
• Normal menstrual cycles with a range of 24-35 days in the absence of oral contraceptives
• Serum FSH less than equal to (≤)5 IU/L on Day -3 and Day -1
• Body mass index (BMI) of 18.5 -25 kg/m^2 (both inclusive)
• Negative serology for human immunodeficiency virus (HIV) antibody, hepatitis B (surface antigen), hepatitis C antibody, and syphilis bacteria
• Healthy according to medical history, physical examination, gynaecological examination, ECG, blood pressure, and laboratory profile of blood and urine
• Negative urine drug screen and alcohol breath test at screening and on Day -1
• Non-smoker or light smoker (≤ 5 cigarettes/day) for at least 6 months prior to trial

Exclusion Criteria:

• Presence or a history of clinically significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems, or presence or history of clinically significant reproductive, psychiatric, immunological, endocrine or metabolic diseases
• Cancer within the last 5 years except for adequately managed basal cell carcinoma and squamous cell carcinoma of the skin
• Pregnancy or breastfeeding
• Current or a history of endocrine abnormalities such as hyperprolactinaemia, polycystic ovary syndrome or other ovarian dysfunction, tumours of the pituitary gland or hypothalamus, thyroid or adrenal disease
• Clinically significant findings on the trans-vaginal ultrasound, cytology, gynaecological or breast examination at screening or on Day -1 including ovarian cysts or tumours of the ovaries or uterus
• Contraindications for the use of gonadotropins and gonadotropin-releasing hormone (GnRH) agonists
• Previously treated with gonadotropins within the last 6 months prior to screening
• History within the last two years or current abuse of alcohol or drugs
• Presence or history of severe allergy or anaphylactic reactions
• Intake of prescribed medication, over-the-counter (OTC) medication, or herbal medicines, with the exceptions of COC, cromoglycate, and paracetamol according to the labelling, within 2 weeks or 5 half-lives of the drug, whichever is longer, prior to first dose of DECAPEPTYL Depot. Topical treatments of bacterial or fungal infection are allowed if stopped before first dose of IMP
• Intake of any non-registered investigational drug within the last 12 weeks preceding screening, or longer if judged by the investigator to possibly influence the outcome of the current trial
• High daily consumption of caffeine-containing beverages (e.g. more than five cups of coffee or equivalent) with a risk of withdrawal symptoms arising during the trial that may confound the safety evaluation
• Blood donation or major blood loss (greater than equal to [≥]500 mL) within the last 8 weeks, or plasma donation with the last 4 weeks preceding the first day of IMP dosing
• Current non-smokers or light smoker with a history of long-term, heavy smoking (>10 pack-years)
• Previously dosed in this trial
• Mental incapacity or language barrier precluding adequate understanding or co-operation
• Considered by the investigator to be unsuitable to participate in the trial for any other reason

The full analysis set (FAS) comprised data from all dosed subjects. Subjects were analyzed according to the actual dose received.

From signed informed consent until the end-of-trial visit (Day 28)

A treatment-emergent AE was any AE occurring after administration of IMP and within the time of residual drug effect, or a pre-treatment AE or pre-existing medical condition that worsened in intensity after start of IMP and within the time of residual drug effect. Only treatment-emergent AEs are presented.